- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05583019
Atopic Dermatitis With Accelerometry and Polysomnography (ADAP) (ADAP)
Device Quantification of Scratch and Sleep in Atopic Dermatitis With Accelerometry and Polysomnography (ADAP) Study
Study Overview
Status
Conditions
Detailed Description
The general procedures include an initial intake appointment on day 1 (can be completed up to 3 days prior in case of scheduling conflicts), two overnight sleep laboratory visits, followed by approximately 12 days of wearing the devices during the participant's normal day-to-day activities and answering questions on a study-provided iPhone in the routine/home setting. The participant will be asked to complete questionnaires related to itch, sleep, pain, and overall Atopic Dermatitis (AD) severity each day, as relevant, and continuously wear wrist-worn accelerometry devices (as specified) during the study.
The study will begin with an initial in-laboratory intake appointment to verify study eligibility to participate in the study. We do our best to screen for study eligibility over the phone, but there are some eligibility requirements that must be assessed in person. This means that at the first appointment, there is a chance that the prospective participant will not be eligible to continue with the remainder of study activities. In the event that they are not eligible to continue at the first in- person appointment, they will be compensated a prorated study amount for their time.
Following the initial intake appointment, the participant will sleep overnight at the sleep laboratory/hotel. The participant will wear both the Apple Watch and the CentrePoint Insights Watch (CPIW) wrist devices, one of each, on both wrists. They will be asked to don the devices at least 6 hours before bedtime on the first overnight visit (day 1) and wear devices continuously (as specified) thereafter. The participant will be video recorded with an infra-red thermal camera (this video is de-identified, and only shows a heat map of their body, so facial features cannot be seen) during the sleep laboratory/hotel visits, wear the wrist accelerometry devices, and complete electronic questionnaires. In addition, on the second overnight in the sleep lab they will also have sensors placed on their head and limbs to monitor their sleep. Both nights, all three devices will also be next to the participant on the night stand, collecting information about their surroundings while they sleep. Upon the completion of the second night in the sleep laboratory (Days 1 and 2), they will then continue to wear wrist accelerometry devices and complete Patient Reported Outcome (PRO) questionnaires at home. The participants will be split into two cohorts (groups): Cohort 1 will wear both the CPIW and the GENEActiv device on both wrists and Cohort 2 will wear both the Apple Watch and GENEActiv device on both wrists. The participants will return to the laboratory on day 8 (+/- 2 days) to swap out devices. Cohort 1 will then wear both the Apple Watch and the GENEActiv device on both wrists and Cohort 2 will wear both the CPIW and GENEActiv device on both wrists for the remaining study days. At the conclusion of the at-home portion of the study, the participant will return the devices and assessments to the laboratory and complete final assessments.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Madisen Wicker, MS
- Phone Number: 413-212-9614
- Email: madisenwicker@symmetryscienceconsulting.com
Study Contact Backup
- Name: Nina Shaafi Kabiri, PhD
- Phone Number: 413-212-9614
- Email: ninakabiri@symmetryscienceconsulting.com
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02118
- Hampton Inn & Suites
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Atopic Dermatitis (AD) Participants:
- Participants aged ≥12 years of age and <75 years of age at Day 1.
- Written informed consent from participant or parent(s)/guardian(s) and assent from the participant (where assent is applicable).
- Participant (and parent(s)/guardian(s)) are willing and able to comply with study instructions, study visits, and procedures.
- Native English speakers or demonstrated fluency in English (participant; and parent(s)/guardian(s) as needed)
- Have a clinical diagnosis of AD according to the criteria of Hanifin and Rajka (concomitant AD treatments are permitted on study).
- Have AD involvement ≥ 5% Treatable % Body Surface Area (BSA) excluding the scalp.
- Have an Investigator's Static Global Assessment (ISGA) score of Mild (2), Moderate (3) or Severe (4) at the screening visit within 14 days of study enrollment.
- Have a minimum Peak Pruritus Numerical Rating Scale (PP-NRS) assessment score of 3 (out of 10).
- Wide Range Achievement Test-4 (WRAT-4) Word Reading Subtest equivalent to 8th grade reading level or greater (for ages ≥18 years only).
Healthy (non-AD) Participants:
- Participants aged ≥12 years of age and <75 years of age at Day 1.
- Written informed consent from participant or parent(s)/guardian(s) and assent from the participant (where assent is applicable).
- Participant (and parent(s)/guardian(s)) are willing and able to comply with study instructions, study visits, and procedures.
- Native English speakers or demonstrated fluency in English (participant; and parent(s)/guardian(s) as needed)
- Does not have suspected or confirmed clinical diagnosis of AD (according to the criteria of Hanifin and Rajka).
- Have an ISGA score of Clear (0) or Almost Clear (1) at the screening visit within 14 days of study enrollment.
- WRAT-4 Word Reading Subtest equivalent to 8th grade reading level or greater (for ages ≥18 years only).
Exclusion Criteria:
Atopic Dermatitis (AD) Participants:
- Has any clinically significant medical disorder, condition, disease (including active or potentially recurrent non-AD dermatological conditions and known genetic dermatological conditions that overlap with AD, such as Netherton syndrome) or clinically significant finding at screening that precludes participant's participation in study activities.
- Allergy to polyurethane resin (strap/wristband component).
- Has documented non-AD related insomnia, sleep apnea or other sleep-related disorders (e.g., narcolepsy, restless legs syndrome, circadian rhythm disorder).
- AD affected surface areas are in a location of device placement.
- If participant has a history of angioedema or anaphylaxis and has had any anaphylactic reactions within the past 6 months.
- Has unstable AD (Total BSA>40%).
- Has a significant active systemic or localized infection, including actively infected AD.
- Has recently (within 30 days of Day 1) participated in or is currently involved in another drug or device research study for AD.
- Has any planned surgical or medical procedure that would overlap with study participation.
- Participants who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or participants who are employees directly involved in the conduct of the study.
- History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL) wine, 12 ounces (360 mL) of beer, or 1.5 ounces (45 mL) of hard liquor) within 6 months of baseline as disclosed by participant during evaluation (for those participants over the age of 21).
- Is a female who is breastfeeding or pregnant, as disclosed by the participant.
- Current shift worker or travel across more than two time zones in the past 2 weeks, and/or during the study period.
- Participants with cardiac pacemakers, electronic pumps or any other implanted medical devices.
Healthy (non-AD) Participants:
- Has any clinically significant medical disorder, condition, disease (including any active/potentially recurrent dermatological conditions (such as Netherton syndrome) or clinically significant finding at screening that precludes participant's participation in study activities.
- Allergy to polyurethane resin (strap/wristband component).
- Has documented clinically diagnosed insomnia, sleep apnea or other sleep-related disorders (e.g., narcolepsy, restless legs syndrome, circadian rhythm disorder).
- If participant has a history of angioedema or anaphylaxis and has had any anaphylactic reactions within the past 6 months.
- Has recently (within 30 days of Day 1) participated in or is currently involved in another drug or device research study.
- Has any planned surgical or medical procedure that would overlap with study participation.
- Participants who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or participants who are employees directly involved in the conduct of the study.
- History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL) wine, 12 ounces (360 mL) of beer, or 1.5 ounces (45 mL) of hard liquor) within 6 months of baseline as disclosed by participant during evaluation (for those participants over the age of 21).
- Is a female who is breastfeeding or pregnant, as disclosed by the participant.
- Current shift worker or travel across more than two time zones in the past 2 weeks, and/or during the study period.
- Participants with cardiac pacemakers, electronic pumps or any other implanted medical devices.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Healthy Control
Those who do not have a diagnosis of Atopic Dermatitis (AD) or eczema and score a Clear (0) or Almost Clear (1) on the Investigator's Static Global Assessment (ISGA) at intake.
|
Thermal Camera
a watch like wearable sensor
Other Names:
a watch like wearable sensor
Other Names:
a watch like wearable sensor
Other Names:
Sleep monitor
|
Mild Atopic Dermatitis (AD)
Those who have a diagnosis of Atopic Dermatitis (AD) or eczema and score a Mild (2) on the Investigator's Static Global Assessment (ISGA) at intake.
|
Thermal Camera
a watch like wearable sensor
Other Names:
a watch like wearable sensor
Other Names:
a watch like wearable sensor
Other Names:
Sleep monitor
|
Moderate Atopic Dermatitis (AD)
Those who have a diagnosis of Atopic Dermatitis (AD) or eczema and score a Moderate (3) on the Investigator's Static Global Assessment (ISGA) at intake.
|
Thermal Camera
a watch like wearable sensor
Other Names:
a watch like wearable sensor
Other Names:
a watch like wearable sensor
Other Names:
Sleep monitor
|
Severe Atopic Dermatitis (AD)
Those who have a diagnosis of Atopic Dermatitis (AD) or eczema and score a Severe (4) on the Investigator's Static Global Assessment (ISGA) at intake.
|
Thermal Camera
a watch like wearable sensor
Other Names:
a watch like wearable sensor
Other Names:
a watch like wearable sensor
Other Names:
Sleep monitor
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quantification of scratch using GENEActiv watches to assess triaxial accelerometry
Time Frame: 14 days +/- 2 days
|
One GENEActiv watch will be used on each wrist at a sampling rate of 100 Hz to measure movement in the x, y, and z direction.
|
14 days +/- 2 days
|
Quantification of scratch using Centrepoint Insights Watches (CPIW) to assess triaxial accelerometry
Time Frame: 14 days +/- 2 days
|
One CPIW watch will be used on each wrist at a sampling rate of 128 Hz to measure movement in the x, y, and z direction.
|
14 days +/- 2 days
|
Quantification of scratch using Apple Watches to assess triaxial accelerometry
Time Frame: 14 days +/- 2 days
|
One Apple Watch will be used on each wrist at a sampling rate of 100 Hz to measure movement in the x, y, and z direction.
|
14 days +/- 2 days
|
Quantification of sleep occurrences using polysomnography
Time Frame: 1 night
|
Polysomnography (PSG) will be used to report the number of sleep occurrences based on the scoring guide provided by the American Academy of Sleep Medicine (AASM).
|
1 night
|
Sleep stage scoring using polysomnography
Time Frame: 1 night
|
Polysomnography (PSG) will be used to report the appropriate sleep staging based on the scoring guide provided by the American Academy of Sleep Medicine (AASM).
The following sleep stages will be scored: Stage W (wakefulness), Stage N1 (NREM 1), Stage N2 (NREM 2), Stage N3 (NREM 3), Stage N (NREM), and Stage R (REM).
|
1 night
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mark B Moss, PhD, SymmetryScience Group, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SSG0001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Videography
-
Shanghai First Maternity and Infant HospitalUnknown
-
Boston UniversityCompleted
-
Boston UniversityCompleted
-
Randy KardonRecruitingMigraine | Traumatic Brain Injury | PhotophobiaUnited States
-
National Cancer Institute (NCI)CompletedHamartoma Syndrome, Multiple | Cowden's DiseaseUnited States